Trinity Biotech plc (TRIB) Monday reported fourth-quarter profit of $4.0 million or 18.4 cents per american depositary receipt, or ADR, rising from last year's $3.7 million or 16.6 cents per ADR.
Revenues for the quarter rose 4 percent to $20.0 million from $19.2 million last year due to higher HIV sales in Africa and USA. Point-of-care revenue increased 12.4 percent while clinical laboratory revenue rose 2.1 percent from last year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org